KASEY BUCHANAN: Open Payments
NPI 1972187607 · DALTON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,507 in 127 payments from 17 companies in 2025. Trend: 2023 $1,641 · 2024 $1,706 · 2025 $2,507
Food & beverage: $2,497Education: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $689 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 18 | $378 |
| Madrigal Pharmaceuticals | 12 | $304 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $279 |
| Janssen Biotech, Inc. | 15 | $246 |
| Gilead Sciences, Inc. | 6 | $158 |
| PFIZER INC. | 5 | $93 |
| QOL Medical, LLC | 3 | $86 |
| Phathom Pharmaceuticals, Inc. | 5 | $79 |
| Aimmune Therapeutics, Inc. | 2 | $46 |
Products named: XIFAXAN, REZDIFFRA, RINVOQ, ENTYVIO, TREMFYA, CREON, LINZESS, VELSIPITY.
Industry payments across GA — which companies pay providers there.
